Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 6/20 | 0.33 |
| ▸ | THRB | P10828 | 6/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3157770 | 0.84 | THRA (0.46) | THRATHRBCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL282207 | 0.82 | LMNA (0.32) | THRATHRBKMT2ALMNA | |
| SCHEMBL281866 | 0.82 | THRB (0.50) | THRATHRB | |
| SCHEMBL282473 | 0.79 | THRA (0.35) | THRATHRBCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL282205 | 0.78 | THRA (0.34) | THRATHRB | |
| SCHEMBL24449999 | 0.77 | THRA (0.33) | THRATHRB | |
| SCHEMBL282515 | 0.75 | THRB (0.45) | THRATHRB | |
| SCHEMBL4350821 | 0.74 | THRA (0.39) | THRATHRBCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL282862 | 0.74 | THRA (0.42) | THRATHRB | |
| SCHEMBL4210344 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428516-A1 | Novel phosphorus-containing thyromimetics | Metabasis Therapeutics, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | THRA 14/4885THRB 41/4885CYP1A2 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.